Erfonrilimab clinical trials
Also written KN046.
How each study uses erfonrilimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the erfonrilimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- KN046
- 16
Studies by the year they started
21 studies that test it; most in 2019 (5)
| Year | Studies |
|---|---|
| 2018 | 2 |
| 2019 | 5 |
| 2020 | 3 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 9
Jiangsu Alphamab Biopharmaceuticals Co., Ltd (9) · Peking University Cancer Hospital & Institute (3) · Peking University (2) · Shanghai Zhongshan Hospital (1) · Suzhou Kintor Pharmaceutical Inc, (1) · Shanghai Pulmonary Hospital, Shanghai, China (1) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (1) · Weill Medical College of Cornell University (1)
Often tested with
Tested in the same studies.
Anbenitamab (2) · Ascrinvacumab (1) · Donafenib tosylate (1) · Donafenib (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test erfonrilimab.
- Dec 2026KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 BlockadePhase 2 · Peking University Cancer Hospital & Institute
Studies
Open first, then newest update. How each study uses erfonrilimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 21
- Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic CancerRecruitingPhase 1/2Shanghai Zhongshan HospitalNCT05832892Written as KN046
- Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GCRecruitingPhase 2Peking UniversityNCT06023758Written as KN046
- A Phase Ib/II Study of GT90001 Combined With KN046 in Solid TumorsRecruitingPhase 1/2Suzhou Kintor Pharmaceutical Inc,NCT04984668Written as GT90001+KN046
- The Efficacy and Safety of KN046 Combined With AxitinibRecruitingPhase 2/3Shanghai Pulmonary Hospital, Shanghai, ChinaNCT06020352Written as KN046 plus Axitinib
- KN 046 Plus Regorafenib in MSS Metastatic Colorectal CancerTerminatedPhase 2Peking University Cancer Hospital & InstituteNCT05985109Written as KN046
- KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 BlockadeActive, not recruitingPhase 2Peking University Cancer Hospital & InstituteNCT06099821Written as KN046
- Study of KN046 in Subjects With Advanced Non-Small Cell Lung CancerCompletedPhase 2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT05420220Written as KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)
- A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal TumorsTerminatedPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT04612712Written as KN046 Injection
- The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular CarcinomaCompletedPhase 2Peking University Cancer Hospital & InstituteNCT04542837Written as KN046
- A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint InhibitorsTerminatedPhase 2Weill Medical College of Cornell UniversityNCT04925947Written as KN046
- KN026 Combined With KN046 in Subjects With HER2 Positive Solid TumorCompletedPhase 1Peking UniversityNCT04040699Written as KN026 combined with KN046
- KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.Active, not recruitingPhase 3Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT05149326Written as KN046
- KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic CarcinomaTerminatedPhase 2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT04469725Written as KN046
- KN046 in Subjects With Advanced Solid Tumors and LymphomaCompletedPhase 1Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT03733951Written as KN046
- A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast CancerCompletedPhase 1/2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT03872791Written as KN046
- KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 AgentTerminatedPhase 2/3Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT05001724Written as KN046
- KN046 in Patients With Advanced Non-small Cell Lung CancerTerminatedPhase 2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT03838848Written as KN046
- KN046 in Subjects With Late Stage Esophageal Squamous Cell CarcinomaCompletedPhase 2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT03925870Written as KN046
- KN046 in Subjects With Advanced Squamous Non-small Cell Lung CancerStatus unknownPhase 3Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT04474119Written as KN046
- KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaStatus unknownPhase 2Shanghai Chest HospitalNCT03927495Written as KN046
See all 21 studies that test erfonrilimab →
Given beside what is tested · 3 — erfonrilimab is usual care or a partner of the new treatment
- KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary CarcinomaNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT05985707Written as KN046
- IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic CancerActive, not recruitingPhase 1/2InxMed (Shanghai) Co., Ltd.NCT05827796Written as KN046
- Study of KN046 With Chemotherapy in First Line Advanced NSCLCStatus unknownPhase 2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT04054531Written as KN046
What changed recently
From the registry's own updates since Oct 18, 2026.
Stopped1
- KN 046 Plus Regorafenib in MSS Metastatic Colorectal CancerTerminatedNov 3, 2026NCT05985109
Codes
What other systems call erfonrilimab · ClinicalTrials.gg INT015898
- UNII (FDA) 9NP50O6YSAERFONRILIMABOne source FDA
- NCI Thesaurus C157632ErfonrilimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 9NP50O6YSA | ERFONRILIMAB | One source FDA |
| NCI Thesaurus | C157632 | Erfonrilimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.